MaxCyte announces a 34% workforce reduction to align resources with strategic priorities, anticipating $13.6 million in annual savings.
Quiver AI Summary
MaxCyte, Inc. has announced a restructuring of its operations, including a reduction of approximately 34% of its global workforce, in order to realign resources with its strategic priorities and significantly cut operating expenses. This move is expected to yield around $13.6 million in annual savings as the company aims to streamline its organization and accelerate towards profitability while maintaining focus on developing next-generation cell therapies. CEO Maher Masoud emphasized the importance of this decision for long-term success and expressed gratitude to departing employees. MaxCyte reaffirmed its outlook for 2025, anticipating flat to a 10% decline in core revenue compared to 2024 and projecting around $5 million in revenue related to its SPL program. The company aims to share more details on the financial implications of this restructuring in its November earnings call.
Potential Positives
- MaxCyte is expected to achieve approximately $13.6 million in annualized savings following the workforce reduction, which could improve its financial flexibility.
- The restructuring aligns resources with strategic priorities, positioning the company for long-term success and a path toward profitability.
- The company maintains a strong cash position, anticipating year-end cash, cash equivalents, and investments to be at least $155 million.
- MaxCyte continues to affirm expected revenue from its SPL program, indicating a stable revenue stream amid restructuring efforts.
Potential Negatives
- The company announced a significant workforce reduction of approximately 34%, indicating potential challenges in sustaining operational efficiency and employee morale.
- MaxCyte's revenue outlook for 2025 is flat to down approximately 10% compared to 2024, which may raise concerns about its growth trajectory and market competitiveness.
FAQ
What is the reason for MaxCyte's workforce reduction?
The workforce reduction is part of a restructuring plan to align resources with strategic priorities and reduce operating expenses.
How many employees will be affected by the restructuring?
Approximately 34% of MaxCyte's global workforce will be reduced as part of the restructuring plan.
What financial savings does MaxCyte expect from this action?
MaxCyte anticipates annualized savings of approximately $13.6 million from the workforce reduction.
When will MaxCyte provide more information on financial impacts?
Further details on the financial impacts will be shared during the third quarter earnings call in November.
What is MaxCyte's core mission?
MaxCyte is focused on advancing the discovery, development, and commercialization of next-generation cell therapies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MXCT Insider Trading Activity
$MXCT insiders have traded $MXCT stock on the open market 6 times in the past 6 months. Of those trades, 5 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MXCT stock by insiders over the last 6 months:
- STANLEY C ERCK purchased 100,000 shares for an estimated $137,220
- RICHARD DOUGLAS purchased 80,000 shares for an estimated $111,039
- MAHER MASOUD (President and CEO) purchased 75,000 shares for an estimated $102,915
- DOUGLAS J SWIRSKY (CHIEF FINANCIAL OFFICER) purchased 50,000 shares for an estimated $64,500
- WILLIAM W BROOKE purchased 50,000 shares for an estimated $64,500
- REKHA HEMRAJANI sold 10,684 shares for an estimated $22,377
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MXCT Hedge Fund Activity
We have seen 63 institutional investors add shares of $MXCT stock to their portfolio, and 58 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MIRABELLA FINANCIAL SERVICES LLP added 2,900,000 shares (+78.4%) to their portfolio in Q2 2025, for an estimated $6,322,000
- BLACKROCK, INC. added 2,033,867 shares (+24.9%) to their portfolio in Q2 2025, for an estimated $4,433,830
- SWEDBANK AB removed 1,390,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,030,200
- ARROWMARK COLORADO HOLDINGS LLC removed 1,235,236 shares (-93.7%) from their portfolio in Q2 2025, for an estimated $2,692,814
- AXA S.A. added 1,215,481 shares (+123.2%) to their portfolio in Q2 2025, for an estimated $2,649,748
- MILLENNIUM MANAGEMENT LLC removed 1,215,179 shares (-88.2%) from their portfolio in Q2 2025, for an estimated $2,649,090
- PORTOLAN CAPITAL MANAGEMENT, LLC removed 1,135,613 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,100,223
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$MXCT Analyst Ratings
Wall Street analysts have issued reports on $MXCT in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stephens & Co. issued a "Overweight" rating on 07/22/2025
To track analyst ratings and price targets for $MXCT, check out Quiver Quantitative's $MXCT forecast page.
Full Release
ROCKVILLE, Md., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. , (Nasdaq: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced a restructuring of its operations to better align resources with its strategic priorities. This plan includes a reduction of approximately 34% of the Company’s global workforce, inclusive of employees engaged through employer-of-record (EOR) arrangements. Anticipated annualized savings as a result of this action are expected to be approximately $13.6 million.
This workforce reduction is part of MaxCyte’s commitment to significantly reduce operating expenses, streamline its organizational structure, and accelerate its path toward profitability. The Company expects this action to yield meaningful cost savings while maintaining focus on its core mission of enabling the next generation of cell therapies.
Consistent with its previously issued outlook, MaxCyte is reiterating that 2025 core revenue is expected to be flat to down approximately 10% compared to 2024. The Company continues to anticipate approximately $5 million in SPL program-related revenue for the full year and expects year-end cash, cash equivalents, and investments to be at least $155 million.
“Today’s decision is important to position MaxCyte for long-term success,” said Maher Masoud, Chief Executive Officer. “We are grateful to our departing colleagues for their many contributions to MaxCyte’s mission and wish them success in future endeavors. This strategic realignment of resources is a significant step forward as part of a broader strategic initiative to drive efficient growth and scale MaxCyte towards profitability. We are developing a culture of continuous improvement throughout the organization and anticipate additional non-employee related opportunities to improve the profitability profile of the company over time. We expect to provide more details on the expected financial impact related to this initiative, as well as the outlook for the remainder of 2025, on our third quarter earnings call in November.”
The Company noted that this workforce reduction represents all the anticipated employee-related actions under the restructuring.
About MaxCyte
At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn .
MaxCyte Contacts:
Investor Relations
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
[email protected]
Media Contact
Oak Street Communications
Kristen White
[email protected]
415.608.6060
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations or financial condition, business strategy, plans and objectives of management for future operations, and anticipated benefits of the announced adjustments to the workforce are forward-looking statements. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.
Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (“SEC”) on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 6, 2025. These documents are available through the Investor Menu, Financials section, under “SEC Filings” on the Investors page of our website at http://investors.maxcyte.com . Any forward-looking statements in this press release are based on our current beliefs and opinions on the relevant subject based on information available to us as of the date of such press release, and you should not rely on forward-looking statements as predictions of future events. We undertake no obligation to update any forward-looking statements made in this press release to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
